Moreover, they setup an orthotopic preclinical model of glioblastoma and observed that combined therapy using anti-LAG-3 and anti-PD-1 antibodies was more effective in terms of increased overall survival than the single therapy. This evidence concerns the gene PDCD1 and glioblastoma.